Here are four points:
1. The procedure is used to treat joint injuries, spine pain and degenerative orthopedic conditions, such as osteoarthritis.
2. The patent focuses on the use of an inflammatory agent to prompt repair of cartilage by stem cells.
3. The new patent is key in protecting Regenexx intellectual property on its proprietary stem cell procedure.
4. Regenexx focuses on developing non-surgical stem cell and blood platelet treatments for common joint injuries and degenerative joint conditions.
More articles on devices:
42 spine, orthopedic devices receive FDA 510(k) clearance in September
Exactech Q3 revenue drops 3%: 10 key notes
Does rhBMP affect pediatric spinal fusion scoliosis patients? 4 key notes
At the Becker’s 32nd Annual Meeting: The Business and Operations of ASCs, taking place October 29-31 in Chicago, ASC leaders, surgeons and healthcare executives will explore strategies to drive growth, enhance operational performance, navigate reimbursement challenges and prepare for the future of ambulatory surgery. Apply for complimentary registration now.
